Independent community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder
Journal of the American Pharmacists Association · 2023
DOI: 10.1016/j.japh.2023.06.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Pharmacists Association, 2023. Verfasst von Rana Zalmai und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Buprenorphine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Substance Abuse and Mental Health Services Administration, Texas Health and Human Services Commission.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
BACKGROUND: Buprenorphine/naloxone (BUP/NX) for opioid use disorder (OUD) is associated with positive health outcomes; however, challenges accessing prescribed BUP/NX at community pharmacies have been identified. OBJECTIVE: The theory of planned behavior was applied to determine whether independent community pharmacists' attitudes toward dispensing BUP/NX for OUD predict intentions to dispense. METHODS: A 40-item survey was administered to 185 Texas Community Pharmacy Enhanced Services Network pharmacists. The survey assessed intentions to dispense BUP/NX (3 items), attitudes toward BUP/NX (24 items), current barriers to dispensing BUP/NX (2 items), and demographics (10 items). Inferential statistics determined associations among pharmacists' attitudes, practice setting characteristics, and intentions to dispense BUP/NX. Regression analysis determined whether attitude predicted intention to dispense BUP/NX, controlling for practice setting and demographic characteristics. RESULTS: Responses were obtained from 82 community independent pharmacists (response rate = 44%). Respondents were predominantly non-Hispanic white (45.8%) and women (56.6%) and practiced in pharmacies with an average 1129.1 (± 1034.5) dispensed prescriptions/week. Pharmacists had positive intentions (6.2 ± 3.5) and attitudes (14.4 ± 24.9) toward dispensing BUP/NX and attitudes did not predict intentions to dispense (P = 0.330). Positive drivers of attitude were related to improving patient outcomes, fulfilling a community need, and absence of conflicts with pharmacists' personal and religious beliefs. A negative driver of attitude was financial reimbursement/loss. Pharmacists dispensing 2000 or more prescriptions/week had higher intentions (b = 3.22, P = 0.014) to dispense than those dispensing less than 500 prescriptions/week. The most common barrier to dispense BUP/NX was "refill was too soon" (54.8%). CONCLUSION: Community independent pharmacists had positive attitudes toward and intentions of dispensing BUP/NX for OUD. However, attitudes did not predict intentions to dispense. Negative drivers of attitudes were related to factors not within pharmacists' control, such as time to refill or financial reimbursement.Future studies focused on community pharmacy-based access to BUP/NX are warranted to elucidate issues that are impactful in improving pharmacists' dispensing intentions and behavior.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Förderung
- Substance Abuse and Mental Health Services Administration
- Texas Health and Human Services Commission
Zitieren
APA
Zalmai, R., Hill, L. G., Loera, L. J., Mosgrove, Q., & Brown, C. (2023). Independent community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder. Journal of the American Pharmacists Association. https://doi.org/10.1016/j.japh.2023.06.010
Vancouver
Zalmai R, Hill LG, Loera LJ, Mosgrove Q, Brown C. Independent community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder. Journal of the American Pharmacists Association. 2023. doi:10.1016/j.japh.2023.06.010
BibTeX
@article{Zalmai2023,
author = {Zalmai, Rana and Hill, Lucas G and Loera, Lindsey J and Mosgrove, Quinn and Brown, Carolyn},
title = {Independent community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder},
journal = {Journal of the American Pharmacists Association},
year = {2023},
doi = {10.1016/j.japh.2023.06.010}
}
EUVIMED